Pablo J. Cagnoni, who serves as President and Global Head of Research and Development at Incyte Corporation (NASDAQ: INCY), disclosed a pair of material equity transactions dated April 17, 2026. On that date Mr. Cagnoni disposed of 18,667 shares of Incyte common stock via a sale priced at $96.50 per share, producing gross proceeds of $1,801,365.
Concurrent with that sale, Mr. Cagnoni exercised employee stock options that resulted in the acquisition of 18,667 shares of common stock. The exercised options were split across two grant tranches: 6,077 shares were purchased at an exercise price of $64.25 per share, and 12,590 shares were purchased at an exercise price of $71.93 per share, giving a combined exercise value of $1,296,045. The exercise prices for the options ranged from $64.25 to $71.93.
Following the sale, Mr. Cagnoni’s direct holdings in Incyte common stock totaled 262,692 shares. That reported ownership figure incorporates an aggregate 257,553 shares that are issuable under previously disclosed restricted stock units and earned performance stock units that remain unvested.
Details on the vesting schedules for the exercised options appear in the company filings. The options associated with the 6,077-share tranche began vesting on July 15, 2024, with an initial 25 percent vesting after one year and the remaining portion vesting monthly thereafter over a three-year period. The options covering 12,590 shares began vesting on January 17, 2025, with the first 25 percent scheduled to vest on July 15, 2025, and the balance vesting monthly over three years.
At the time of these insider transactions, Incyte shares were trading around $96.25 and had posted a roughly 70 percent total return over the prior 12 months. Market metrics noted for the company include a market capitalization of $19.1 billion and a price-to-earnings ratio of 15.14. An InvestingPro analysis mentioned alongside the disclosures characterized the stock as appearing undervalued at current levels and assigned a financial health rating of "GREAT," noting that Incyte’s balance sheet shows more cash than debt.
These equity moves were disclosed in the context of broader corporate developments. Incyte said full results from its Phase 3 frontMIND study evaluating tafasitamab in first-line diffuse large B-cell lymphoma will be presented at the American Society of Clinical Oncology Annual Meeting in 2026. The company indicated those results are expected to support global regulatory submissions.
Analyst activity and trial-readouts remain part of the public narrative surrounding the stock. H.C. Wainwright reiterated a Buy rating on Incyte, citing potential for the company’s drug povorcitinib to be deployed in early-line treatment for hidradenitis suppurativa. Separately, Citizens sustained a Market Perform rating for Incyte following updated clinical trial data presented at a medical conference. William Blair also kept a Market Perform rating after reviewing long-term data from Incyte’s hidradenitis suppurativa programs.
On the corporate governance front, Incyte disclosed that board member Susanne Schaffert will resign in April 2026, and the company stated that her decision to step down is not related to any disagreement with the company. The firm also reported Phase III STOP-HS1/HS2 study results for its hidradenitis suppurativa program that demonstrated a statistically significant benefit at week 12, although the top-line outcomes were described as slightly below expectations.
Together, the insider transactions, upcoming Phase 3 presentations, and analyst commentary form the most recent set of public datapoints for investors tracking Incyte. The exercise of options and the subsequent sale by Mr. Cagnoni are routine mechanisms by which executives realize value or manage equity positions, and the company provided specifics on both the exercise prices and the vesting schedules associated with the option grants.
Summary of transactions
- Sale: 18,667 shares at $96.50 per share - proceeds $1,801,365.
- Exercise: 18,667 shares via options - combined exercise cost $1,296,045 (exercise prices $64.25 and $71.93).
- Direct common stock ownership after sale: 262,692 shares, including 257,553 shares issuable under unvested RSUs and performance units.
Note on limitations: The information above is limited to the details disclosed in the company filings and accompanying analysis cited at the time of the transactions. No additional forecasts, valuations, or forward-looking statements are included beyond those provided in those disclosures.